Seretide

Seretide

Salmeterol/fluticasone propionate, see there.
Mentioned in ?
References in periodicals archive ?
In Europe, Seretide sales were down 19% AER, 20% CER to [pounds sterling]599 million (13% volume decline and a 7% price decline).
Growth in new Respiratory products offset the decline in Seretide.
These medicines are for psoriasis (Dovobet Gel), asthma (Seretide Evohaler 250mcg), asthma and chronic obstructive pulmonary disease (COPD) (DuoResp Spiromax 160mcg/4.5mcg Inhaler) and COPD only (Incruse Ellipta 55mcg Inhaler and Spiriva 18mcg Inhalation Powder Capsules).
They treated BO patients with NAC (1,200-1,800 mg/day), inhaled Seretide 125-250/25 (2 puffs BID), and azithromycin (250 mg, three times/week).
The Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which indicated that patients with adequately controlled asthma were able to switch to the once-daily FF/VI 100/25, from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function.
The recall of Accuhaler Ventolin and Seretide inhalers used in the treatment of asthmatic patients does not involve the Malaysian market, said Health
Additionally, Glaxo Wellcome's Seretide Accuhaler, used for the maintenance of preventative treatment of asthma, is being recalled from hospitals, pharmacies, dispensing practices, retailers and wholesalers in the UK.
The other lot being recalled from from hospitals, pharmacies, dispensing practices, retailers and wholesalers is the Seretide Accuhaler, used for preventative treatment of asthma.
The recalled products are: | Ventolin 200mcg - Accuhaler 1x60D 786G | Expiry date: 05/2019 | Ventolin 200mcg - Accuhaler 1x60D 754P | Expiry date: 05/2019 | Seretide 50/250mcg - Accuhaler 1x60D 5K8W | Expiry date: 04/2019
For example, in Europe, the following pMDI products recommend the AeroChamber Plus brand of VHCs: Airomir, AirSalb, Alvesco, Atrovent, Flutiform, Fostair, Qvar, Seretide, and Sirdupla.
Novartis today announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide (salmeterol/fluticasone) 50/500 mcg to Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg 1 .